Cerebrospinal Fluid Melanin-Concentrating Hormone (MCH) and Hypocretin-1 (HCRT-1, Orexin-A) in Alzheimer's Disease

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Schmidt, Frank M ^a   Kratzsch, Juergen ^a   Gertz, Hermann Josef ^a   Tittmann, Mandy ^a   Jahn, Ina ^a   Pietsch, Uta Carolin ^a   Kaisers, Udo X ^a   Thiery, Joachim ^a   Hegerl, Ulrich ^a   Schönknecht, Peter ^a  

^a UNIVERSITY HOSPITAL LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MELANIN CONCENTRATING HORMONE; OREXIN A; TAU PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID LEVEL; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE SEVERITY; FEMALE; FLUORESCENCE ANALYSIS; HUMAN; IMMUNOASSAY; MALE; MINI MENTAL STATE EXAMINATION; OUTCOME ASSESSMENT; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE;

AGED; ALZHEIMER DISEASE; CASE-CONTROL STUDIES; FEMALE; HUMANS; HYPOTHALAMIC HORMONES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MELANINS; NEUROPEPTIDES; PITUITARY HORMONES; SEX CHARACTERISTICS;

EID: 84877146102     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0063136     Document Type: Article

References (59)

1. Fernández M, Gobartt AL, Balañá M, (2010) Behavioural symptoms in patients with Alzheimer's disease and their association with cognitive impairment. BMC Neurol 10: 87.
2. McCurry SM, Ancoli-Israel S, (1985) Sleep Dysfunction in Alzheimer's Disease and Other Dementias. Curr Treat Options Neurol 5: 261-272.
3. McDuff T, Sumi SM, (1985) Subcortical degeneration in Alzheimer's disease. Neurology 35: 123-6.
4. Ogomori K, Kitamoto T, Tateishi J, Sato Y, Suetsugu M, (1989) Beta-protein amyloid is widely distributed in the central nervous system of patients with Alzheimer's disease. Am J Pathol 134: 243-51.
5. Simpson J, Yates CM, Watts AG, Fink G, (1988) Congo red birefringent structures in the hypothalamus in senile dementia of the Alzheimer type. Neuropathol Appl Neurobiol 14: 381-93.
6. Saper CB, Fuller PM, Pedersen NP, Lu J, Scammell TE, (2010) Sleep state switching. Neuron 68: 1023-42.
7. Hassani OK, Lee MG, Jones BE, (2009) Melanin-concentrating hormone neurons discharge in a reciprocal manner to orexin neurons across the sleep-wake cycle. Proc Natl Acad Sci U S A 106: 2418-22.
8. Adamantidis A, de Lecea L (2009) A role for Melanin-Concentrating Hormone in learning and memory. Peptides 30: 2066-70. Review.
9. Bayer L, Eggermann E, Serafin M, Grivel J, Machard D, et al. (2005) Opposite effects of noradrenaline and acetylcholine upon hypocretin/orexin versus melanin concentrating hormone neurons in rat hypothalamic slices. Neuroscience 130: 807-811.
10. Van den Pol AN, Acuna-Goycolea C, Clark KR, Ghosh PK, (2004) Physiological properties of hypothalamic MCH neurons identified with selective expression of reporter gene after recombinant virus infection. Neuron 42: 635-52.
11. Hervieu GJ, Cluderay JE, Harrison D, Meakin J, Maycox P, et al. (2000) The distribution of the mRNA and protein products of the melanin-concentrating hormone (MCH) receptor gene, slc-1, in the central nervous system of the rat. Eur J Neurosci 12: 1194-216.
12. Peyron C, Sapin E, Leger L, Luppi PH, Fort P (2009) Role of the melanin-concentrating hormone neuropeptide in sleep regulation. Peptides 30: 2052-9. Review.
13. Verret L, Goutagny R, Fort P, Cagnon L, Salvert D, et al. (2003) A role of melanin-concentrating hormone producing neurons in the central regulation of paradoxical sleep. BMC Neurosci 4: 19.
14. Sakamaki R, Uemoto M, Inui A, Asakawa A, Ueno N, et al. (2005) Melanin-concentrating hormone enhances sucrose intake. Int J Mol Med 15: 1033-9.
15. Smith DG, Davis RJ, Rorick-Kehn L, Morin M, Witkin JM, et al. (2006) McKinzie DL, Nomikos GG, Gehlert DR. Melanin-concentrating hormone-1 receptor modulates neuroendocrine, behavioral, and corticolimbic neurochemical stress responses in mice. Neuropsychopharmacology 31: 1135-45.
16. Millan MJ, Gobert A, Panayi F, Rivet JM, Dekeyne A, et al. (2008) The melanin-concentrating hormone1 receptor antagonists, SNAP-7941 and GW3430, enhance social recognition and dialysate levels of acetylcholine in the frontal cortex of rats. Int J Neuropsychopharmacol 11: 1105-22.
17. Shimada M, Tritos NA, Lowell BB, Flier JS, Maratos-Flier E, (1998) Mice lacking melanin-concentrating hormone are hypophagic and lean. Nature 396: 670-4.
18. Chung S, Parks GS, Lee C, Civelli O (2011) Recent updates on the melanin-concentrating hormone (MCH) and its receptor system: lessons from MCH1R antagonists. J Mol Neurosci 43: 115-21. Review.
19. Lambe EK, Olausson P, Horst NK, Taylor JR, Aghajanian GK, (2005) Hypocretin and nicotine excite the same thalamocortical synapses in prefrontal cortex: correlation with improved attention in rat. J Neurosci 25: 5225-9.
20. Arrigoni E, Mochizuki T, Scammell TE, (2010) Activation of the basal forebrain by the orexin/hypocretin neurones. Acta Physiol (Oxf) 198: 223-35.
21. Delazer M, Högl B, Zamarian L, Wenter J, Gschliesser V, et al. (2011) Executive functions, information sampling, and decision making in narcolepsy with cataplexy. Neuropsychology 25: 477-87.
22. Naumann A, Daum I, (2003) Narcolepsy: pathophysiology and neuropsychological changes. Behav Neurol 14: 89-98.
23. Raggi A, Plazzi G, Pennisi G, Tasca D, Ferri R, (2011) Cognitive evoked potentials in narcolepsy: a review of the literature. Neurosci Biobehav Rev 35: 1144-53.
24. Gozzi A, Turrini G, Piccoli L, Massagrande M, Amantini D, et al. (2011) Functional magnetic resonance imaging reveals different neural substrates for the effects of orexin-1 and orexin-2 receptor antagonists. PLoS One 6: e16406.
25. Fronczek R, van Geest S, Frölich M, Overeem S, Roelandse FW, et al. (2012) Hypocretin (orexin) loss in Alzheimer's disease. Neurobiol Aging 33: 1642-50.
26. Wennström M, Londos E, Minthon L, Nielsen HM, (2012) Altered CSF Orexin and α-Synuclein Levels in Dementia Patients.J Alzheimers Dis. 29: 125-32.
27. Lessig S, Ubhi K, Galasko D, Adame A, Pham E, et al. (2010) Remidios K, Chang M, Hansen LA, Masliah E. Reduced hypocretin (orexin) levels in dementia with Lewy bodies. Neuroreport 21: 756-60.
28. Baumann CR, Hersberger M, Bassetti CL, (2006) Hypocretin-1 (orexin A) levels are normal in Huntington's disease. J Neurol 253: 1232-3.
29. Kang JE, Lim MM, Bateman RJ, Lee JJ, Smyth LP, et al. (2009) Cirrito JR, Fujiki N, Nishino S, Holtzman DM. Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science 326: 1005-7.
30. Slats D, Claassen J, Lammers GJ, Melis RJ, Verbeek MM, et al. (2012) Association between Hypocretin-1 and Amyloid-beta 42 Cerebrospinal Fluid Levels in Alzheimer's Disease and Healthy Controls. Curr Alzheimer Res. 9: 1119-25.
31. Friedman LF, Zeitzer JM, Lin L, Hoff D, Mignot E, et al. (2007) In Alzheimer disease, increased wake fragmentation found in those with lower hypocretin-1. Neurology 68: 793-4.
32. Kessler BA, Stanley EM, Frederick-Duus D, Fadel J, (2011) Age-related loss of orexin/hypocretin neurons. Neuroscience 178: 82-8.
33. Stanley EM, Fadel J, (2012) Aging-related deficits in orexin/hypocretin modulation of the septohippocampal cholinergic system. Synapse 66: 445-52.
34. Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, et al. (2010) Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol 9: 1118-27.
35. Morris JC, Heyman A, Mohs RC, Hughes JP, van Belle G, et al. (1989) The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology 39: 1159-65.
36. Russell EW, (1982) Factor analysis of the Revised Wechsler Memory Scale tests in a neuropsychological battery. Percept Mot Skills 54: 971-4.
37. Shulman KI, (2000) Clock-drawing: is it the ideal cognitive screening test? Int J Geriatr Psychiatry 15: 548-61.
38. Moses JA Jr (2004). Test review-Comprehensive Trail Making Test (CTMT). Arch Clin Neuropsychol 19: 703-8. Review.
39. First MB, Spitzer RL, Gibbon M, Williams JBW (1997) Structured Clinical Interview for DSM-IV Axis I disorders (SCID I). New York: Biometric Research Department.
40. Hamilton M, (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23: 56-62.
41. Burkart M, Heun R, Maier W, Benkert O, (1998) Dementia screening in routine clinical practice. A comparative analysis of MMSE, SIDAM and ADAS. Nervenarzt 69: 983-90.
42. Salomon RM, Ripley B, Kennedy JS, Johnson B, Schmidt D, et al. (2003) Diurnal variation of cerebrospinal fluid hypocretin-1 (orexin-A) levels in control and depressed subjects. Biol Psychiatry 54: 96-104.
43. Mungas D (1991) In-office mental status testing: a practical guide. Geriatrics 46: 54-8, 63, 66.
44. Cecon E, Markus RP, (2011) Relevance of the chronobiological and non-chronobiological actions of melatonin for enhancing therapeutic efficacy in neurodegenerative disorders. Recent Pat Endocr Metab Immune Drug Discov 5: 91-9.
45. Guyon A, Conductier G, Rovere C, Enfissi A, Nahon JL (2009) Melanin-concentrating hormone producing neurons: Activities and modulations. Peptides 30: 2031-9. Review.
46. Adamantidis A, Thomas E, Foidart A, Tyhon A, Coumans B, et al. (2005) Disrupting the melanin-concentrating hormone receptor 1 in mice leads to cognitive deficits and alterations of NMDA receptor function. Eur J Neurosci (21) (): 2837-44.
47. Monzon ME, de Souza MM, Izquierdo LA, Izquierdo I, Barros DM, et al. (1999) Melanin-concentrating hormone (MCH) modifies memory retention in rats. Peptides 20: 1517-9.
48. Varas M, Pérez M, Ramírez O, de BarioglioSR, (2002) Melanin concentrating hormone increase hippocampal synaptic transmission in the rat. Peptides 23: 151-5.
49. Ellenbogen JM, Payne JD, Stickgold R (2006) The role of sleep in declarative memory consolidation: passive, permissive, active or none? Curr Opin Neurobiol 16: 716-22. Review.
50. Wang G, Grone B, Colas D, Appelbaum L, Mourrain P, (2011) Synaptic plasticity in sleep: learning, homeostasis and disease. Trends Neurosci 34: 452-63.
51. Rolls A, Colas D, Adamantidis A, Carter M, Lanre-Amos T, et al. (2011) Optogenetic disruption of sleep continuity impairs memory consolidation. Proc Natl Acad Sci U S A 108: 13305-10.
52. Gerashchenko D, Murillo-Rodriguez E, Lin L, Xu M, Hallett L, et al. (2003) Relationship between CSF hypocretin levels and hypocretin neuronal loss. Exp Neurol 184: 1010-6.
53. Gao S, Hendrie HC, Hall KS, Hui S, (1998) The relationships between age, sex, and the incidence of dementia and Alzheimer disease: a meta-analysis. Arch Gen Psychiatry 55: 809-15.
54. Clinton LK, Billings LM, Green KN, Caccamo A, Ngo J, et al. (2007) Age-dependent sexual dimorphism in cognition and stress response in the 3xTg-AD mice. Neurobiol Dis 28: 76-82.
55. Silva A, Andersen ML, De Mello MT, Bittencourt LR, Peruzzo D, et al. (2008) Tufik S.Gender and age differences in polysomnography findings and sleep complaints of patients referred to a sleep laboratory. Braz J Med Biol Res 41: 1067-75.
56. Silveyra P, Cataldi NI, Lux-Lantos V, Libertun C, (2009) Gonadal steroids modulated hypocretin/orexin type-1 receptor expression in a brain region, sex and daytime specific manner. Regul Pept 158: 121-6.
57. Jöhren O, Neidert SJ, Kummer M, Dominiak P, (2002) Sexually dimorphic expression of prepro-orexin mRNA in the rat hypothalamus. Peptides 23: 1177-80.
58. Schmidt FM, Arendt E, Steinmetzer A, Bruegel M, Kratzsch J, et al. (2011) CSF-hypocretin-1 levels in patients with major depressive disorder compared to healthy controls. Psychiatry Res 190: 240-243.
59. Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, et al. (2010) Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 9: 119-28.